Aline Simoneti Fonseca

Dr. Aline Simoneti Fonseca

Pelé Pequeno Príncipe Research Institute
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
DRDaiane Rosolen
Daiane Rosolen
ESEmanuelle Nunes de Souza
Emanuelle Nunes de Souza
RMRafael Diogo Marchi
Rafael Diogo Marchi
MTMaria Vitoria Tofolo
Maria Vitoria Tofolo
VAValquíria C. Antunes
Valquíria C. Antunes
LCLuciane Cavalli
Luciane Cavalli
MicroRNAs (miRNAs) are involved in the regulation of mitochondrial function and homeostasis, and in the modulation of cell metabolism, by targeting known oncogenes and tumor suppressor genes of metabolic-related signaling pathways involved in the hallmarks of cancer. This systematic review focuses on articles describing the role, association, and/or involvement of miRNAs in regulating the mitochondrial function and metabolic reprogramming of cancer cells. Following the PRISMA guidelines, the articles reviewed were published from January 2010 to September 2022, with the search terms “mitochondrial microRNA” and its synonyms (mitochondrial microRNA, mitochondrial miRNA, mito microRNA, or mitomiR), “reprogramming metabolism,” and “cancer” in the title or abstract). Thirty-six original research articles were selected, revealing 51 miRNAs with altered expression in 12 cancers: bladder, breast, cervical, colon, colorectal, liver, lung, melanoma, osteosarcoma, pancreatic, prostate, and tongue. The actions of miRNAs and their corresponding target genes have been reported mainly in cell metabolic processes, mitochondrial dynamics, mitophagy, apoptosis, redox signaling, and resistance to chemotherapeutic agents. Altogether, these studies support the role of miRNAs in the metabolic reprogramming hallmark of cancer cells and highlight their potential as predictive molecular markers of treatment response and/or targets that can be used for therapeutic intervention.

1 March 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AFAline Simoneti Fonseca
Aline Simoneti Fonseca
ARAnelisa Ramão
Anelisa Ramão
MBMatheus Carvalho Bürger
Matheus Carvalho Bürger
JSJorge Estefano Santana de Souza
Jorge Estefano Santana de Souza
DZDalila Lucíola Zanette
Dalila Lucíola Zanette
WJWilson Araujo Silva Jr
Wilson Araujo Silva Jr
Background: Colorectal cancer (CRC) is one of the most common cancers worldwide; it is the fourth leading cause of death in the world and the third in Brazil. Mutations in theAPC, DCC, KRASandTP53genes have been associated with the progression of sporadic CRC, occurring at defined pathological stages of the tumor progression and consequently modulating several genes in the corresponding signaling pathways. Therefore, the identification of gene signatures that occur at each stage during the CRC progression is critical and can present an impact on the diagnosis and prognosis of the patient. In this study, our main goal was to determine these signatures, by evaluating the gene expression of paired colorectal adenoma and adenocarcinoma samples to identify novel genetic markers in association to the adenoma-adenocarcinoma stage transition.Methods: Ten paired adenoma and adenocarcinoma colorectal samples were subjected to microarray gene expression analysis. In addition, mutations inAPC, KRASandTP53genes were investigated by DNA sequencing in paired samples of adenoma, adenocarcinoma, normal tissue, and peripheral blood from ten patients.Results: Gene expression analysis revealed a signature of 689 differentially expressed genes (DEG) (fold-change> 2,p< 0.05), between the adenoma and adenocarcinoma paired samples analyzed. Gene pathway analysis using the 689 DEG identified important cancer pathways such as remodeling of the extracellular matrix and epithelial-mesenchymal transition. Among these DEG, theETV4stood out as one of the most expressed in the adenocarcinoma samples, further confirmed in the adenocarcinoma set of samples from the TCGA database. Subsequent in vitro siRNA assays againstETV4resulted in the decrease of cell proliferation, colony formation and cell migration in the HT29 and SW480 colorectal cell lines. DNA sequencing analysis revealedKRASandTP53gene pathogenic mutations, exclusively in the adenocarcinomas samples.Conclusion: Our study identified a set of genes with high potential to be used as biomarkers in CRC, with a special emphasis on theETV4gene, which demonstrated involvement in proliferation and migration.

26 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
BSBruna Mayumi Sugita
Bruna Mayumi Sugita
YRYara Rodriguez
Yara Rodriguez
AFAline Simoneti Fonseca
Aline Simoneti Fonseca
ESEmanuelle Nunes de Souza
Emanuelle Nunes de Souza
BKBhaskar Kallakury
Bhaskar Kallakury
LCLuciane Cavalli
Luciane Cavalli
MiR-150-5p is frequently deregulated in cancer, with expression and mode of action varying according to the tumor type. Here, we investigated the expression levels and role of miR-150-5p in the aggressive breast cancer subtype triple-negative breast cancer (TNBC). MiR-150-5p expression levels were analyzed in tissue samples from 113 patients with invasive breast cancer (56 TNBC and 57 non-TNBC) and 41 adjacent non-tumor tissues (ANT). Overexpression of miR-150-5p was observed in tumor tissues compared with ANT tissues and in TNBC compared with non-TNBC tissues. MiR-150-5p expression levels were significantly associated with high tumor grades and the Caucasian ethnicity. Interestingly, high miR-150-5p levels were associated with prolonged overall survival. Manipulation of miR-150-5p expression in TNBC cells modulated cell proliferation, clonogenicity, migration, and drug resistance. Manipulation of miR-150-5p expression also resulted in altered expression of its mRNA targets, including epithelial-to-mesenchymal transition markers, MYB, and members of the SRC pathway. These findings suggest that miR-150-5p is overexpressed in TNBC and contributes to the aggressiveness of TNBC cells in vitro.

Verified
Journal Article
Open access
PDF file
SBShristi Bhattarai
Shristi Bhattarai
BSBruna Mayumi Sugita
Bruna Mayumi Sugita
LCLuciane Cavalli
Luciane Cavalli
AFAline Simoneti Fonseca
Aline Simoneti Fonseca
LCLuciane Cavalli
Luciane Cavalli
Ritu AnejaRitu Aneja
Ritu Aneja
Triple-negative breast cancer (TNBC) can be further classified into androgen receptor (AR)-positive TNBC and AR-negative TNBC or quadruple-negative breast cancer (QNBC). Here, we investigated genomic instability in 53 clinical cases by array-CGH and miRNA expression profiling. Immunohistochemical analysis revealed that 64% of TNBC samples lacked AR expression. This group of tumors exhibited a higher level of copy number alterations (CNAs) and a higher frequency of cases affected by CNAs than TNBCs. CNAs in genes of the chromosome instability 25 (CIN25) and centrosome amplification (CA) signatures were more frequent in the QNBCs and were similar between the groups, respectively. However, expression levels of CIN25 and CA20 genes were higher in QNBCs. miRNA profiling revealed 184 differentially expressed miRNAs between the groups. Fifteen of these miRNAs were mapped at cytobands with CNAs, of which eight (miR-1204, miR-1265, miR-1267, miR-23c, miR-548ai, miR-567, miR-613, and miR-943), and presented concordance of expression and copy number levels. Pathway enrichment analysis of these miRNAs/mRNAs pairings showed association with genomic instability, cell cycle, and DNA damage response. Furthermore, the combined expression of these eight miRNAs robustly discriminated TNBCs from QNBCs (AUC = 0.946). Altogether, our results suggest a significant loss of AR in TNBC and a profound impact in genomic instability characterized by CNAs and deregulation of miRNA expression.

22 January 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
MSMarilesia Ferreira Souza
Marilesia Ferreira Souza
ICIlce Mara Syllos Colus
Ilce Mara Syllos Colus
AFAline Simoneti Fonseca
Aline Simoneti Fonseca
VAValquíria Casanova Antunes
Valquíria Casanova Antunes
DKDeepak Kumar
Deepak Kumar
LCLuciane Cavalli
Luciane Cavalli
Prostate cancer (PCa) is a clinically heterogeneous disease, where deregulation of epigenetic events, such as miRNA expression alterations, are determinants for its development and progression. MiR-182-5p, a member of the miR-183 family, when overexpressed has been associated with PCa tumor progression and decreased patients’ survival rates. In this study, we determined the regulatory role of miR-182-5p in modulating aggressive tumor phenotypes in androgen-refractory PCa cell lines (PC3 and DU-145). The transient transfection of the cell lines with miR-182-5p inhibitor and mimic systems, significantly affected cell proliferation, adhesion, migration, and the viability of the cells to the chemotherapeutic agents, docetaxel, and abiraterone. It also affected the protein expression levels of the tumor progression marker pAKT. These changes, however, were differentially observed in the cell lines studied. A comprehensive biological and functional enrichment analysis and miRNA/mRNA interaction revealed its strong involvement in the epithelial-mesenchymal transition (EMT) process; expression analysis of EMT markers in the PCa transfected cells directly or indirectly modulated the analyzed tumor phenotypes. In conclusion, miR-182-5p differentially impacts tumorigenesis in androgen-refractory PCa cells, in a compatible oncomiR mode of action by targeting EMT-associated pathways.

8 December 2023 in Life Sciences
Verified
Journal Article
Closed access
FBFernanda Costa Brandão Berti
Fernanda Costa Brandão Berti
MTMaria Vitoria Tofolo
Maria Vitoria Tofolo
ESEmanuelle Nunes de Souza
Emanuelle Nunes de Souza
RMRafael Marchi
Rafael Marchi
LOLarissa Miyuki Okano
Larissa Miyuki Okano
LCLuciane Cavalli
Luciane Cavalli